Abstract 1775P
Background
ICB can be an effective treatment option for a subset of sarcoma patients (pts). Identifying biomarkers of response and resistance is essential to determining pts most likely to benefit.
Methods
We conducted a retrospective analysis of PB and tumor samples from sarcoma pts enrolled in 5 distinct ICB-based clinical trials. Pre-treatment PB samples from 185 pts were analyzed using 11-color flow cytometry. RNA sequencing of 58 baseline tumor samples was used to classify the TME into 4 subtypes by consensus clustering of single-sample functional gene expression signature enrichment scores. We investigated associations between PB and tumor characteristics and clinical outcomes.
Results
In a multivariable analysis accounting for study treatment and histology, higher proportion of TIM-3+/CD8+PD-1- T cells in the PB was associated with shorter PFS and OS (hazard ratio [HR] 1.44, 95% confidence interval [CI] 1.17-1.77, p < 0.001, false discovery rate [FDR] q = 0.0376 and HR 1.70, 95% CI 1.35-2.13, p < 0.001, FDR q < 0.001, respectively). TME subtype was associated with overall response rate (ORR) and PFS (Table). In a multivariable analysis accounting for TME subtype, higher proportion of these TIM-3+ T cells remained associated with shorter PFS and OS (HR 1.9, CI 1.22-2.96, p = 0.006 and HR 1.84, CI 1.12-3.02, p = 0.022, respectively). Table: 1775P
TME Subtype | N | ORR (CI)1 | Median PFS in months (CI)2 | Median OS in months (CI)3 |
Immune-enriched, non-fibrotic | 9 | 78% (40-97) | NR | NR |
Immune-enriched, fibrotic | 23 | 14% (2.9-35) | 2.1 (1.8-5.4) | 11 (9.4-22) |
Depleted | 8 | 13% (0.32-53) | 1.7 (1.6-NR) | 7.8 (6.2-NR) |
Fibrotic | 18 | 0% (0-19) | 1.8 (1.6-5.5) | 12 (4.8-NR) |
1Fisher’s exact p < 0.0012Log-rank p = 0.0023Log-rank p = 0.2
Conclusions
Sarcoma pts with a lower proportion of PB TIM-3+/CD8+PD-1- T cells and a baseline immune-enriched non-fibrotic TME are more likely to benefit from ICB. These factors are independently associated with outcomes and could serve as complementary biomarkers for predicting response to ICB.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Rosenbaum.
Funding
Has not received any funding.
Disclosure
E. Rosenbaum: Financial Interests, Personal, Stocks/Shares: Iovance Biotherapeutics, PMV Pharmaceuticals; Financial Interests, Institutional, Local PI: Incyte Corporation, Arcus Biosciences, GSK. C.M. Kelly: Financial Interests, Personal, Other, Employment, Stock, or other Ownership Interest: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: Exicure, Immunicum; Financial Interests, Institutional, Research Funding: Agios, Amgen, Merck, Incyte, Kartos, Epicure, Xencor. S. Movva: Financial Interests, Institutional, Coordinating PI: Tracon, Pfizer, Merck, BMS, Clovis, Ascentage; Financial Interests, Institutional, Local PI: PTC therapeutics, Hutchinson Medipharma. J. Chan: Financial Interests, Institutional, Other, Received antibodies in part of a collaboration for a grant.: Cytek; Financial Interests, Institutional, Other, My research work in lung cancer was funded as part of a sponsored research agreement between my PI and the company.: Ono Pharmaceutical. P. Chi: Financial Interests, Personal, Other, Advisor and Consultant: Ningbo NewBay Medical Technology; Financial Interests, Institutional, Funding, Clinical trial funding: Ningbo NewBay Medical Technology; Financial Interests, Personal and Institutional, Steering Committee Member, Clinical Trial: Ningbo NewBay Medical Technology, Deciphera; Financial Interests, Institutional, Funding, clinical trial: Deciphera; Financial Interests, Institutional, Funding, Trial: Pfizer. M. Dickson: Financial Interests, Institutional, Other: Sumitomo Dainippon Pharma Oncology, Aadi; Financial Interests, Institutional, Principal Investigator: Lilly. R.G. Maki: Financial Interests, Personal, Other, DSMB participation: Deciphera; Financial Interests, Personal, Other, Consultant to serve as Medical Monitor: Peel Therapeutics; Financial Interests, Personal, Invited Speaker, Sarcoma content for web site: Physician's Education Resource; Financial Interests, Personal, Writing Engagement, Sarcoma content editor: UptoDate; Financial Interests, Personal, Advisory Board, Advisory board: GSK; Financial Interests, Personal, Advisory Board: Medtronic; Financial Interests, Personal, Other, Associate Editor, JCO: American Society of Clinical Oncology; Financial Interests, Personal and Institutional, Coordinating PI, Clinical trial support and steering committee - brigimadlin studies: Boehringer Ingelheim; Financial Interests, Personal and Institutional, Coordinating PI, Investigator initiated trial with pembrolizumab: GSK. P. Wong: Financial Interests, Personal, Other, Professional services and activities: Leap Therapeutics Inc.; Non-Financial Interests, Personal, Other, Professional services and activities: Sellas Life Science Group. K. Panageas: Financial Interests, Personal, Stocks/Shares: 23andMe. W.D. Tap: Financial Interests, Personal, Leadership Role: Certis Oncology Solutions, Atropos, Innova Therapeutics; Financial Interests, Personal, Advisory Role: EMD Serono, Lilly, Daiichi, Deciphera, C4, Mundipharma, Ascendo, Ayala Pharma, Kowa Pharma, Servier, Bayer, Epizyme, Cogent, Medpacto, Foghorn, Amgen; Financial Interests, Institutional, Research Funding: Novartis, Lilly, Plexxikon, Daiichi Sankyo, Tracon, Blueprint, Immune Design, Bioatla, Deciphera. S.P. D'Angelo: Financial Interests, Personal, Advisory Role: EMD Serono, Amgen, Nektar, Immune design, GSK, Incyte, Merck, Adaptimmiune, Immunocore; Financial Interests, Institutional, Research Funding: EMD Serono, Amgen, Merck, Incyte, Nektar, BMS, Deciphera; Financial Interests, Personal, Other, Travel: Adaptimmune, EMD Serono, Nektar. All other authors have declared no conflicts of interest.
Resources from the same session
1740P - Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial
Presenter: Yuhong Zhou
Session: Poster session 06
1741P - Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt
Presenter: Paolo G. Casali
Session: Poster session 06
1742P - Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study
Presenter: Pau Mascaró Baselga
Session: Poster session 06
1743P - A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma
Presenter: Zhiguo Luo
Session: Poster session 06
1745P - How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center
Presenter: Sebastian Diaz
Session: Poster session 06
1746P - Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project
Presenter: Kenji Tsuchihashi
Session: Poster session 06
1747P - Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study
Presenter: Evelyne Roets
Session: Poster session 06
1748P - A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS)
Presenter: Xi Guo
Session: Poster session 06
1749P - Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified?
Presenter: Tania Moussa
Session: Poster session 06
1750P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Gale Rizzae Mercado Alcala
Session: Poster session 06